Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease

Table 3 Clinical score does not correlate with pathology in the early stages of disease (day 1–10).

	Bioluminescence (fold induction)				Clinical score
	Brain		Spinal cord		Brain		Spinal cord
	R	P	R	P	R	P	R	P
Astrogliosis (GFAP)	0.704	0.015	0.713	0.010	0.120	0.298	0.233	0.501
Microgliosis (CD68)	0.886	<0.0001	0.478	0.141	0.352	0.298	0.040	0.914
T cell infiltration (CD4)	0.549	0.081	0.774	0.004	0.388	0.247	0.472	0.147
Weight loss	0.823	0.0001	0.811	0.0001	R= 0.354; P= 0.286

Bioluminescence correlates with disease progression in the early stage (day 1–10), but clinical score does not. GFAP-luc mice were immunized with MOG_35–55 emulsified in CFA plus pertussis toxin. Mice were evaluated for clinical signs and bioluminescence and sacrificed at day 3, 5, 7 and 10 (n = 11 mice). The same mice were part of the analysis shown in Table 1. The correlation was analyzed by Pearson correlation analysis. R: correlation coefficient.

ISSN: 1742-2094